Case Report
The role of rivaroxaban in left ventricular thrombi
Mahmoud Abdelnaby 1
, Abdallah Almaghraby 2
, Ola Abdelkarim 2
, Yehia Saleh 3
, Basma Hammad 4
, Haitham Badran 5
, Ola Abdelkarim 2
, Yehia Saleh 3
, Basma Hammad 4
, Haitham Badran 5
1Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, University of Alexandria; Alexandria-Egypt
2Department of Cardiology, Faculty of Medicine, University of Alexandria; Alexandria-Egypt
3Department of Internal Medicine, Michigan State University; East Lansing, Michigan-United States of America
4Department of Cardiology, Massachusetts General Hospital; Boston-United States of America
5Department of Cardiology, Ain Shams University; Cairo-Egypt
2Department of Cardiology, Faculty of Medicine, University of Alexandria; Alexandria-Egypt
3Department of Internal Medicine, Michigan State University; East Lansing, Michigan-United States of America
4Department of Cardiology, Massachusetts General Hospital; Boston-United States of America
5Department of Cardiology, Ain Shams University; Cairo-Egypt
Keywords: Left ventricular apical thrombi, Novel Oral Anticoagulants (NOACs), Rivaroxaban, Vitamin K Antagonist (VKA), Acute Coronary Syndromes (ACS), Dual Antiplatelet Therapy (DAPT)